<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Insights dev</title>
    <link>https://resilience.com/insights-dev</link>
    <description>Insights dev</description>
    <language>en</language>
    <pubDate>Wed, 23 Sep 2026 12:51:13 GMT</pubDate>
    <dc:date>2026-09-23T12:51:13Z</dc:date>
    <dc:language>en</dc:language>
    <item>
      <title>Redefining CAR-T Speed and Strength with DAR-T™: A Conversation with Nicholas Kirian Test</title>
      <link>https://resilience.com/insights-dev/redefining-car-t-speed-and-strength-with-dar-t-a-conversation-with-nicholas-kirian-test</link>
      <description>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://resilience.com/insights-dev/redefining-car-t-speed-and-strength-with-dar-t-a-conversation-with-nicholas-kirian-test" title="" class="hs-featured-image-link"&gt; &lt;img src="https://resilience.com/hubfs/DAR-T%20Q-A%20-%20Blog.png" alt="DAR-T" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;&lt;strong&gt;In this Q&amp;amp;A, Nicholas Kirian, Senior Manager of MSAT, discusses how DAR-T™, an autologous CAR-T platform, is addressing longstanding challenges in cell therapy manufacturing. From reducing cycle times to improving cell potency and persistency, DAR-T is redefining what is possible in the production of life-saving therapies.&lt;/strong&gt;&lt;/p&gt;</description>
      <content:encoded>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://resilience.com/insights-dev/redefining-car-t-speed-and-strength-with-dar-t-a-conversation-with-nicholas-kirian-test" title="" class="hs-featured-image-link"&gt; &lt;img src="https://resilience.com/hubfs/DAR-T%20Q-A%20-%20Blog.png" alt="DAR-T" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;&lt;strong&gt;In this Q&amp;amp;A, Nicholas Kirian, Senior Manager of MSAT, discusses how DAR-T™, an autologous CAR-T platform, is addressing longstanding challenges in cell therapy manufacturing. From reducing cycle times to improving cell potency and persistency, DAR-T is redefining what is possible in the production of life-saving therapies.&lt;/strong&gt;&lt;/p&gt;  
&lt;img src="https://track.hubspot.com/__ptq.gif?a=20797991&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fresilience.com%2Finsights-dev%2Fredefining-car-t-speed-and-strength-with-dar-t-a-conversation-with-nicholas-kirian-test&amp;amp;bu=https%253A%252F%252Fresilience.com%252Finsights-dev&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <category>Cell Therapy</category>
      <category>Technology</category>
      <category>Resources</category>
      <pubDate>Wed, 23 Sep 2026 12:22:20 GMT</pubDate>
      <guid>https://resilience.com/insights-dev/redefining-car-t-speed-and-strength-with-dar-t-a-conversation-with-nicholas-kirian-test</guid>
      <dc:date>2026-09-23T12:22:20Z</dc:date>
      <dc:creator>Resilience</dc:creator>
    </item>
  </channel>
</rss>
